Literature DB >> 18667295

Risk factors and mechanisms of non-alcoholic steatohepatitis.

Chantal A Rivera1.   

Abstract

The worldwide proportion of overweight and obese individuals has increased yearly for more than a decade. Along with rates of obesity, the incidence of co-morbid conditions such as type 2 diabetes, cardiovascular disease and liver disease has also increased. The form of liver disease associated with obesity is termed non-alcoholic steatohepatitis (NASH) due to the histological similarities to livers of chronic alcoholics. NASH has been observed in adult as well as pediatric populations; however, the etiology of this disease is still unknown. This review outlines some of the risk factors commonly associated with NASH and describes molecular mechanisms proposed to underlie disease pathogenesis.

Entities:  

Year:  2008        PMID: 18667295      PMCID: PMC2600439          DOI: 10.1016/j.pathophys.2008.04.003

Source DB:  PubMed          Journal:  Pathophysiology        ISSN: 0928-4680


  69 in total

1.  Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4.

Authors:  Gyongyi Szabo; Arumugam Velayudham; Laszlo Romics; Pranoti Mandrekar
Journal:  Alcohol Clin Exp Res       Date:  2005-11       Impact factor: 3.455

2.  Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy.

Authors:  S Yamagishi; K Nakamura; T Matsui; Masayoshi Takeuchi
Journal:  Med Hypotheses       Date:  2005-10-10       Impact factor: 1.538

3.  Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients.

Authors:  Steven F Solga; Jeanne M Clark; Amir R Alkhuraishi; Michael Torbenson; Alireza Tabesh; Michael Schweitzer; Anna Mae Diehl; Thomas H Magnuson
Journal:  Surg Obes Relat Dis       Date:  2005 Jan-Feb       Impact factor: 4.734

4.  Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency.

Authors:  Richard Kirsch; Vivian Clarkson; Robert C Verdonk; Adrian D Marais; Enid G Shephard; Bernard Ryffel; Pauline de la M Hall
Journal:  J Gastroenterol Hepatol       Date:  2006-01       Impact factor: 4.029

5.  Regional patterns of fat distribution.

Authors:  P Björntorp
Journal:  Ann Intern Med       Date:  1985-12       Impact factor: 25.391

6.  Chronic intermittent hypoxia predisposes to liver injury.

Authors:  Vladimir Savransky; Ashika Nanayakkara; Angelica Vivero; Jianguo Li; Shannon Bevans; Philip L Smith; Michael S Torbenson; Vsevolod Y Polotsky
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

7.  Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery.

Authors:  Florence Harnois; Simon Msika; Jean-Marc Sabaté; Charlotte Mechler; Pauline Jouet; Jeanine Barge; Benoit Coffin
Journal:  Obes Surg       Date:  2006-02       Impact factor: 4.129

8.  Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression.

Authors:  Philip A Kern; Gina B Di Gregorio; Tong Lu; Negah Rassouli; Gouri Ranganathan
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

Review 9.  Leptin in the regulation of immunity, inflammation, and hematopoiesis.

Authors:  G Fantuzzi; R Faggioni
Journal:  J Leukoc Biol       Date:  2000-10       Impact factor: 4.962

10.  Chemokines control fat accumulation and leptin secretion by cultured human adipocytes.

Authors:  C C Gerhardt; I A Romero; R Cancello; L Camoin; A D Strosberg
Journal:  Mol Cell Endocrinol       Date:  2001-04-25       Impact factor: 4.102

View more
  10 in total

1.  Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease.

Authors:  Maria Stepanova; Noreen Hossain; Arian Afendy; Kellie Perry; Zachary D Goodman; Ancha Baranova; Zobair Younossi
Journal:  Obes Surg       Date:  2010-01-30       Impact factor: 4.129

2.  FOXO1 increases CCL20 to promote NF-κB-dependent lymphocyte chemotaxis.

Authors:  Hongming Miao; Yang Zhang; Zhongyan Lu; Liqing Yu; Lixia Gan
Journal:  Mol Endocrinol       Date:  2012-01-12

3.  Non-alcoholic steatohepatitis and influence of age and gender on histopathologic findings.

Authors:  Nargess Ebrahimi Daryani; Nasser Ebrahimi Daryani; Seyed Moayed Alavian; Ali Zare; Seyed-Mohammad Fereshtehnejad; Mohammad Reza Keramati; Mohammad Reza Pashaei; Peiman Habibollahi
Journal:  World J Gastroenterol       Date:  2010-09-07       Impact factor: 5.742

4.  Celecoxib ameliorates non-alcoholic steatohepatitis in type 2 diabetic rats via suppression of the non-canonical Wnt signaling pathway expression.

Authors:  Feng Tian; Ya Jie Zhang; Yu Li; Ying Xie
Journal:  PLoS One       Date:  2014-01-03       Impact factor: 3.240

5.  Germacrone cooperates with dexmedetomidine to alleviate high-fat diet-induced type 2 diabetes mellitus via upregulating AMPKα1 expression.

Authors:  Yang Sun; Lanlan Li; Jun Wu; Bing Gong; Haiyan Liu
Journal:  Exp Ther Med       Date:  2019-09-09       Impact factor: 2.447

6.  Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects.

Authors:  Satoko Takahashi; Marenao Tanaka; Masato Furuhashi; Norihito Moniwa; Masayuki Koyama; Yukimura Higashiura; Arata Osanami; Yufu Gocho; Hirofumi Ohnishi; Keita Numata; Takashi Hisasue; Nagisa Hanawa; Tetsuji Miura
Journal:  Sci Rep       Date:  2021-04-21       Impact factor: 4.379

Review 7.  Multi-Target Approaches in Metabolic Syndrome.

Authors:  Felix F Lillich; John D Imig; Ewgenij Proschak
Journal:  Front Pharmacol       Date:  2021-03-12       Impact factor: 5.810

8.  Independent association of plasma xanthine oxidoreductase activity with hypertension in nondiabetic subjects not using medication.

Authors:  Masato Furuhashi; Yukimura Higashiura; Masayuki Koyama; Marenao Tanaka; Takayo Murase; Takashi Nakamura; Seigo Akari; Akiko Sakai; Kazuma Mori; Hirofumi Ohnishi; Shigeyuki Saitoh; Kazuaki Shimamoto; Tetsuji Miura
Journal:  Hypertens Res       Date:  2021-06-11       Impact factor: 3.872

Review 9.  Steatosis and steatohepatitis: complex disorders.

Authors:  Kira Bettermann; Tabea Hohensee; Johannes Haybaeck
Journal:  Int J Mol Sci       Date:  2014-06-03       Impact factor: 5.923

10.  Extract of a polyherbal formulation ameliorates experimental nonalcoholic steatohepatitis.

Authors:  Mohammed Azeemuddin; Mohamed Rafiq; Suryakanth Dattatraya Anturlikar; Lakkavalli Mohan Sharath Kumar; Pralhad Sadashiv Patki; Uddagiri Venkanna Babu; Ramakrishnan Shyam
Journal:  J Tradit Complement Med       Date:  2015-01-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.